Claims for Patent: 10,376,579

Summary for Patent: 10,376,579

Title:	Nanoparticle complexes of albumin, paclitaxel, and anti-VEGF antibody for treatment of cancer
Abstract:	This document provides materials related to treating cancer (e.g., skin cancer). For example, materials relating to the use of a composition containing albumin-containing nanoparticle/antibody complexes (e.g., albumin-bound paclitaxel/anti-VEGF polypeptide antibody complexes) to treat cancer (e.g., skin cancer) are provided).
Inventor(s):	Markovic; Svetomir N. (Rochester, MN), Nevala; Wendy K. (Rochester, MN)
Assignee:	Mayo Foundation for Medical Education and Research (Rochester, MN)
Application Number:	15/052,336
Patent Claims:	1. An antibody-albumin nanoparticle complex comprising albumin, a bevacizumab antibody, and paclitaxel, wherein the nanoparticle complex has been pre-formed in vitro by mixing an aqueous albumin-paclitaxel nanoparticle with the antibody under conditions to form the nanoparticle complex, such that the nanoparticle complex has VEGF binding specificity, and wherein the complex has a diameter of between 0.1 .mu.m and 1 .mu.m. 2. The antibody-albumin nanoparticle complex of claim 1, said complex having a diameter of between 0.1 .mu.m and about 0.9 .mu.m. 3. The antibody-albumin nanoparticle complex of claim 1, said complex having a diameter of between about 0.1 .mu.m and 0.3 .mu.m. 4. The antibody-albumin nanoparticle complex of claim 1, wherein the ratio of albumin-paclitaxel nanoparticle to antibody is between 5:1 and 1:25. 5. The antibody-albumin nanoparticle complex of claim 1, wherein said nanoparticle complex comprises an alkylating agent. 6. The antibody-albumin nanoparticle complex of claim 5, wherein said alkylating agent is a platinum compound. 7. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and antibody-albumin nanoparticle complexes, said nanoparticle complexes comprising albumin, a bevacizumab antibody, and paclitaxel, wherein the nanoparticle complexes have been pre-formed in vitro by mixing aqueous albumin-paclitaxel nanoparticles with the antibody under conditions to form the nanoparticle complexes, such that the nanoparticle complexes have VEGF binding specificity, and wherein the average diameter of said complexes is between 0.1 .mu.m and 1 .mu.m. 8. The pharmaceutical composition of claim 7, wherein the average diameter of said complexes is between 0.1 .mu.m and 0.9 .mu.m. 9. The pharmaceutical composition of claim 7, wherein the average diameter of said complexes is between 0.1 .mu.m and 0.3 .mu.m. 10. The pharmaceutical composition of claim 7, wherein the ratio of albumin-paclitaxel nanoparticle to antibody is between 5:1 and 1:2.5. 11. The pharmaceutical composition of claim 7, wherein said composition comprises an alkylating agent. 12. The pharmaceutical composition of claim 11, wherein said alkylating agent is a platinum compound. 13. The pharmaceutical composition of claim 7 which is formulated for injection. 14. The pharmaceutical composition of claim 7, wherein the pharmaceutically acceptable carrier is saline, water, lactic acid, mannitol, or a combination thereof. 15. A method of making an antibody-albumin nanoparticle complex, the method comprising mixing in vitro an aqueous albumin-paclitaxel nanoparticle with a bevacizumab antibody under conditions to form the nanoparticle complex, wherein the complex has a diameter of between 0.1 .mu.m and 1 .mu.m.

Details for Patent 10,376,579

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2032-10-01